- Home
- MKZR vs IMRN Comparison
MKZR vs IMRN Comparison
Compare MKZR & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKZR
- IMRN
- Stock Information
- Founded
- MKZR 2012
- IMRN 1994
- Country
- MKZR United States
- IMRN Australia
- Employees
- MKZR N/A
- IMRN N/A
- Industry
- MKZR
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- MKZR
- IMRN Health Care
- Exchange
- MKZR Nasdaq
- IMRN Nasdaq
- Market Cap
- MKZR 10.3M
- IMRN 9.2M
- IPO Year
- MKZR N/A
- IMRN N/A
- Fundamental
- Price
- MKZR $0.63
- IMRN $1.72
- Analyst Decision
- MKZR
- IMRN Strong Buy
- Analyst Count
- MKZR 0
- IMRN 1
- Target Price
- MKZR N/A
- IMRN $5.00
- AVG Volume (30 Days)
- MKZR 536.4K
- IMRN 656.2K
- Earning Date
- MKZR 08-11-2025
- IMRN 09-08-2025
- Dividend Yield
- MKZR 55.53%
- IMRN N/A
- EPS Growth
- MKZR N/A
- IMRN N/A
- EPS
- MKZR N/A
- IMRN N/A
- Revenue
- MKZR $23,037,348.00
- IMRN $4,048,286.00
- Revenue This Year
- MKZR N/A
- IMRN N/A
- Revenue Next Year
- MKZR N/A
- IMRN N/A
- P/E Ratio
- MKZR N/A
- IMRN N/A
- Revenue Growth
- MKZR 52.64
- IMRN 82.90
- 52 Week Low
- MKZR $0.60
- IMRN $1.50
- 52 Week High
- MKZR $5.50
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- MKZR N/A
- IMRN 45.31
- Support Level
- MKZR N/A
- IMRN $1.60
- Resistance Level
- MKZR N/A
- IMRN $1.80
- Average True Range (ATR)
- MKZR 0.00
- IMRN 0.10
- MACD
- MKZR 0.00
- IMRN -0.01
- Stochastic Oscillator
- MKZR 0.00
- IMRN 34.09
About MKZR MacKenzie Realty Capital Inc.
Mackenzie Realty Capital Inc is a company which is a Real estate investment trust (REIT). The company has one reportable segment, income-producing real estate properties which consists of activities related to investing in real estate.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.